Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.31 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.31 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34465075 | 0.90 | NR1H2 (0.31) | MAP4K4HDAC1HDAC2 | |
| SCHEMBL34466776 | 0.90 | PARP1 (0.34) | MAP4K4HDAC1HDAC2 | |
| SCHEMBL34464960 | 0.90 | PARP1 (0.34) | MAP4K4HDAC1HDAC2 | |
| SCHEMBL34465221 | 0.89 | USP30 (0.32) | MAP4K4SCN9A | |
| SCHEMBL34466268 | 0.89 | SCN9A (0.31) | MAP4K4SCN9ASMARCA2SMARCA4PBRM1 | |
| SCHEMBL34465127 | 0.89 | USP30 (0.32) | MAP4K4SCN9A | |
| SCHEMBL35212331 | 0.89 | USP30 (0.32) | MAP4K4SCN9A | |
| SCHEMBL35212572 | 0.89 | SCN9A (0.31) | MAP4K4SCN9ASMARCA2SMARCA4PBRM1 | |
| SCHEMBL35212050 | 0.88 | SUV39H2 (0.35) | SCN9A | |
| SCHEMBL35212051 | 0.88 | SUV39H2 (0.35) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108510-A1 | PYRAZOLYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, CYP11B2 | MAP4K4 3490/4885SCN9A 2447/4885HDAC1 3634/4885 |
| US-20260108509-A1 | 6-MEMBERED HETEROARYL INDAZOLE CGAS INHIBITORS AND USES THEREOF | CGAS, GBA3, GBA1 | MAP4K4 4358/4885SCN9A 2416/4885HDAC1 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.